Minerva Neurosciences | NERV - Pre Tax Profit


Minerva Neurosciences reported $22.51M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Adma Biologics USD 61.59M 14.07M Dec/2025
ALKERMES USD -61.93M 122.3M Mar/2026
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
AstraZeneca USD 3.91B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Cipla INR 7.49B 4.2B Mar/2026
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD 56.84M 63.78M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Takeda JPY -52.48B 186.34B Mar/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024